medigraphic.com
ISSN 0035-0052 (Print)

2017, Number 6

<< Back Next >>

Rev Mex Pediatr 2017; 84 (6)

Survival of pediatric patients with acute lymphoblastic leukemia at the Hospital de la Niñez Oaxaqueña

Quero-Hernández A, Montes-Jiménez AD, Álvarez-Solís RM, Reyes-Gómez U, Ballesteros-del Olmo JC, Quero-Estrada A

Language: Spanish
References: 24
Page: 230-236
PDF size: 222.49 Kb.


ABSTRACT

Introduction: Acute lymphoblastic leukemia (ALL) represents the main malignancy in pediatrics; in our country, an incidence of 75.3 cases/one million is estimated. The aim of the present study is to estimate the overall survival in a group of children with ALL who were treated at the Oaxaca Children’s Hospital with the protocol proposed by the National Council for Prevention and Treatment in Childhood and Adolescence (CENSIA). Material and methods: During the period from January 2010 to December 2014, 79 patients with ALL were treated with a method proposed by the CENSIA. Risk classification was based on age and white blood cell count at diagnosis. The analysis estimated the measures of central tendency and overall survival curves. Results: Of the 79 patients, 27.8% were at habitual risk, 55 at high risk (69.6%), and two cases were very high risk. The overall survival at three years for the standard risk group was 81.8%, and for the high risk group, 78.3% (p = 0.18). Conclusions: The overall survival of children with ALL treated in this hospital is somewhat lower than reported, which seems to be related to a higher number of high-risk patients.


REFERENCES

  1. Li J, Thompson TD, Miller JW, Pollack LA, Stewart SL. Cancer incidence among children and adolescents in the United States, 2001-2003. Pediatrics. 2008; 121(6): e1470-e1477.

  2. Rivera-Luna R, Correa-González C, Altamirano-Alvarez E, Sánchez-Zubieta F, Cárdenas-Cardós R, Escamilla-Asian G et al. Incidence of childhood cancer among Mexican children registered under a public medical insurance program. Int J Cancer. 2013; 132(7): 1646-1650.

  3. Quero-Hernández A, Rosas-Sumano B, Álvarez-Solís R, Vargas-Vallejo M. Neoplasias malignas en los niños del Hospital General de Oaxaca, entre 1999-2011. Rev Mex Pediatr. 2013; 80(4): 136-141.

  4. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010; 115(16): 3206-3214.

  5. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood. 2008; 111(12): 5477-5485.

  6. Carroll WL, Bhojwani D, Min DJ, Raetz E, Relling M, Davies S et al. Pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2003: 102-131.

  7. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009; 360(26): 2730-2741.

  8. Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC et al. Long-term results of St. Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 2010; 24(2): 371-382.

  9. Jiménez-Hernández E, Jaimes-Reyes EZ, Arellano-Galindo J, García-Jiménez X, Tiznado-García HM, Dueñas-González MT et al. Survival of Mexican Children with acute lymphoblastic leukaemia under treatment with the protocol from the Dana-Farber Cancer Institute 00-01. Biomed Res Int. 2015; 2015: 576950.

  10. López-Hernández MA, Alvarado-Ibarra M, Jiménez-Alvarado RM, De Diego-Flores JE, González-Avante CM. Adolescentes con leucemia aguda linfoblástica de novo: eficacia y seguridad de un protocolo pediátrico versus uno de adultos. Gac Méd Méx. 2008; 144(6): 485-489.

  11. Reyes-López A, Miranda-Lora L, Ruíz-Cano J, Lee M, Dorantes-Acosta E, Zapata-Tarrés M et al. Factores pronósticos de supervivencia en pacientes pediátricos con leucemia linfoblástica aguda afiliados al seguro popular. Bol Med Hosp Infant Mex. 2012; 69(3): 197-204.

  12. Autores del LAL. Leucemia aguda linfoblástica. En: Rivera-Luna R, editor. Protocolos técnicos. Cáncer en niños. México: Editores de Textos Mexicanos; 2010. pp. 9-60.

  13. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996; 14(1): 18-24.

  14. Pui CH, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St. Jude Children’s Research Hospital. Blood. 2004; 104(9): 2690-2696.

  15. Kamps WA, van der Pal-de Bruin KM, Veerman AJ, Fiocco M, Bierings M, Pieters R. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia. 2010; 24(2): 309-319.

  16. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007; 109(3): 896-904.

  17. Xu H, Cheng C, Devidas M, Pei D, Fan Y, Yang W et al. ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2012; 30(7): 751-757.

  18. Sims RP. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia. J Oncol Pharm Pract. 2016; 22(1): 76-81.

  19. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012; 30(14): 1663-1669.

  20. Escherich G, Horstmann MA, Zimmermann M, Janka-Schaub GE; COALL study group. Cooperative Study Group for Childhood Acute Lymphoblastic Leukaemia (COALL): long-term results of trials 82,85,89,92 and 97. Leukemia. 2010; 24(2): 298-308.

  21. Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008; 111(9): 4477-4489.

  22. Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000; 95(11): 3310-3322.

  23. Kamps WA, Bökkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia. 2002; 16(6): 1099-1111.

  24. Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008; 111(9): 4477-4489.




2020     |     www.medigraphic.com